Mesenchymal stem cell-derived exosomal microRNA-367-3p mitigates lower limb ischemia/reperfusion injury in mouse skeletal muscle via EZH2 targeting
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Huanhuan Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China. Hauptthemen laut MEDLINE: MicroRNAs, Enhancer of Zeste Homolog 2 Protein, Exosomes, Muscle, Skeletal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Hebei Province Medical Science Research, Hebei Natural Science Foundation.
Abstract (Originalsprache)
Objective
This study aimed to investigate the protective effect of bone marrow mesenchymal stem cell-derived exosomes (BMSCs-exo) against lower limb ischemia/reperfusion (I/R) injury-induced pyroptosis in skeletal muscle.
Methods
A mouse model of lower limb I/R injury was utilized to assess the impact of BMSCs-exo, particularly when loaded with microRNA-367-3p (miR-367-3p), on pyroptosis. Histological examination, wet weight/dry weight ratio measurements, and luciferase assays were employed to elucidate the mechanisms involved. Key findings BMSCs-exo effectively suppressed pyroptosis in injured skeletal muscle tissue. Loading BMSCs-exo with miR-367-3p enhanced this protective effect by downregulating key pyroptosis-related proteins. Luciferase assays identified enhancer of zeste homolog 2 (EZH2) as a direct target of miR-367-3p in BMSCs-exo.
Conclusions
BMSCs-exo loaded with miR-367-3p safeguarded mouse skeletal muscle against pyroptosis-induced I/R injury by targeting EZH2. These findings offer valuable insights into potential therapeutic strategies for lower limb I/R injuries, emphasizing the therapeutic potential of BMSCs-exo in mitigating tissue damage caused by pyroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China.
- Department of Neurology, Neurological Laboratory of Hebei Province, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China.
- Department of Vascular Surgery, Shijiazhuang Hospital of Traditional Chinese Medicine 050000, Hebei, China.
- The Department of Orthopedic, Wuqiang County People's Hospital, Hengshui, Hebei 053300, China.
- Department of Vascular Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
ORCID-Profile: Yanrong Zhang
Förderung
- Hebei Province Medical Science Research
- Hebei Natural Science Foundation
Zitieren
APA
Sun, H., Wang, J., Bi, W., Zhang, F., Zhang, K., Tian, X., Gao, X., & Zhang, Y. (2024). Mesenchymal stem cell-derived exosomal microRNA-367-3p mitigates lower limb ischemia/reperfusion injury in mouse skeletal muscle via EZH2 targeting. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae086
Vancouver
Sun H, Wang J, Bi W, Zhang F, Zhang K, Tian X, et al. Mesenchymal stem cell-derived exosomal microRNA-367-3p mitigates lower limb ischemia/reperfusion injury in mouse skeletal muscle via EZH2 targeting. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae086
BibTeX
@article{Sun2024,
author = {Sun, Huanhuan and Wang, Jueqiong and Bi, Wei and Zhang, Feng and Zhang, Kai and Tian, Xitao and Gao, Xiang and Zhang, Yanrong},
title = {Mesenchymal stem cell-derived exosomal microRNA-367-3p mitigates lower limb ischemia/reperfusion injury in mouse skeletal muscle via EZH2 targeting},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae086}
}
EUVIMED